Here are the Form 4 insider transactions from LB Pharmaceuticals Inc (LBRX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow LBRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LBRX filings page.
LB Pharmaceuticals Inc. Chief Financial Officer Joseph M. Miller received a direct employee stock option award covering 200,000 shares of common stock on October 9, 2026. The options have an exercise price of $37.22 per share and expire October 8, 2036. Vesting is subject to Miller’s continuous service through each vesting date.
LB Pharmaceuticals Inc. granted Chief Medical Officer Susan Gani Kozauer 200,000 employee stock options on October 9, 2026, with an exercise price of $37.22 per share and an expiration date of October 8, 2036. One fourth of the option shares vest on September 14, 2027; the remainder vest monthly over the following three years beginning September 30, 2027, subject to Kozauer’s continuous service through each vesting date.
LB Pharmaceuticals Inc. received an insider report from Deep Track–affiliated entities. On 2026-07-30, Deep Track Biotechnology Master Fund, Ltd., a ten percent holder, purchased 286205.0000 Pre-Funded Warrants to buy LBRX common stock at $34.9399 per warrant, bringing its direct Pre-Funded Warrant position to 664649.0000. Each warrant is immediately exercisable at $0.0001 per share, does not expire, and is subject to a 9.99% beneficial ownership limitation. A separate indirect position of 93925.0000 Pre-Funded Warrants is reported as held by Deep Track Special Opportunities Fund, LP. Deep Track Capital, LP and David Kroin may be deemed beneficial owners through their roles but disclaim beneficial ownership except to the extent of their pecuniary interests.
LB Pharmaceuticals director Robert R. Ruffolo received a stock option grant covering 10,000 shares of common stock. The options have an exercise price of $27.95 per share and expire on June 2, 2036.
According to the terms, 100% of the shares underlying the option vest on the earlier of June 3, 2027 or the date of the company’s next annual meeting of stockholders, as long as he remains in continuous service through the vesting date. After this grant, Ruffolo holds 10,000 stock options directly.
LB PHARMACEUTICALS INC director Ran Nussbaum received a new stock option grant. He was awarded options for 10,000 shares of common stock at an exercise price of $27.95 per share, expiring on June 2, 2036.
All 10,000 underlying shares vest on the earlier of June 3, 2027 or the company’s next annual meeting of stockholders, provided he remains in continuous service through that date. Following this compensation grant, he holds 10,000 stock options directly, with no open‑market buying or selling reported in this filing.
LB Pharmaceuticals Inc director Rebecca Luse received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $27.95 per share and expire on June 2, 2036. All underlying shares vest on the earlier of June 3, 2027 or the company’s next annual stockholder meeting, as long as she remains in continuous service.
LB Pharmaceuticals director Robert A. Lenz received a grant of stock options covering 12,500 shares of common stock. The options carry an exercise price of $27.95 per share and expire on June 2, 2036, functioning as equity-based compensation rather than an open-market trade.
Footnotes explain that 2,500 of these options represent a prorated annual grant for a prior year under the company’s non-employee director compensation policy. All 12,500 underlying shares vest 100% on the earlier of June 3, 2027 or the company’s next annual meeting of stockholders, contingent on Mr. Lenz’s continuous service.
LB Pharmaceuticals director Rekha Hemrajani received a new stock option grant tied to the company’s common stock. The award covers 10,000 shares with an exercise price of $27.95 per share and expires on June 2, 2036.
These options were granted as compensation and not purchased on the open market. All 10,000 underlying shares vest on the earlier of June 3, 2027 or the company’s next annual meeting of stockholders, if she remains in continuous service through that date. Following this grant, she holds 10,000 stock options directly.
LB Pharmaceuticals Inc director granted stock options as part of equity compensation. Director William P. Kane Jr received options for 10,000 shares of common stock, giving him the right to buy those shares at an exercise price of $27.95 per share until June 2, 2036.
According to the filing, 100% of the shares underlying the option vest on the earlier of June 3, 2027 or the date of the company’s next annual meeting of stockholders, if he continues to serve through that date. After this grant, he holds options for 10,000 shares directly.
LB Pharmaceuticals Inc. director Garland J. Scott received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $27.95 per share and expire on June 2, 2036. This is a compensation-related award, not an open-market purchase or sale.
According to the terms, 100% of the shares underlying the option vest on the earlier of June 3, 2027 or the date of the company’s next annual meeting of stockholders, subject to Scott’s continuous service through the vesting date. Following the grant, Scott holds 10,000 stock options directly.
LB Pharmaceuticals director Robert A. Lenz received a grant of stock options for 20,000 shares of common stock. The options have an exercise price of $23.78 per share and expire on March 5, 2036. They vest in three equal annual installments on March 6, 2027, March 6, 2028, and March 6, 2029, contingent on continued service. Following this grant, he holds 20,000 derivative securities directly.
LB Pharmaceuticals Inc. reported insider purchases of pre-funded warrants by Deep Track-affiliated funds. On February 6, 2026, Deep Track Biotechnology Master Fund, Ltd. acquired 378,444 pre-funded warrants, and Deep Track Special Opportunities Fund, LP acquired 93,925 pre-funded warrants, each at $21.1699 per warrant.
The pre-funded warrants are exercisable immediately at an exercise price of $0.0001 per share of common stock and do not expire. Their terms cap beneficial ownership at 9.99% of LB Pharmaceuticals’ outstanding common stock, preventing exercises that would put the holder and its affiliates above that threshold. Deep Track Capital, LP and David Kroin are reporting persons and state they may be deemed beneficial owners only to the extent of their pecuniary interests.
LB Pharmaceuticals reported that its chief commercial officer received an employee stock option grant covering 195,000 shares of common stock. The option, dated 12/10/2025, has an exercise price of $21.36 per share and expires on 12/09/2035.
One fourth of the shares vest on 11/10/2026, with the remaining shares vesting in 36 equal monthly installments on the last calendar day of each month starting 12/31/2026, subject to the officer’s continuous service. Following this grant, the officer beneficially owns 195,000 stock options, held directly.